MCID: ORL007
MIFTS: 62

Oral Cavity Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oral Cavity Cancer

MalaCards integrated aliases for Oral Cavity Cancer:

Name: Oral Cavity Cancer 12 15 17
Malignant Neoplasm of Anterior Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Floor of Mouth 12
Malignant Tumor of Anterior Floor of Mouth 12
Malignant Tumor of Lateral Floor of Mouth 12
Malignant Tumor of the Floor of the Mouth 12
Malignant Neoplasm of Floor of Mouth 12
Malignant Tumor of Floor of Mouth 6
Malignant Neoplasm of Mouth 74
Oral Cavity Carcinoma 74

Classifications:



Summaries for Oral Cavity Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of anterior portion of floor of mouth, is related to lip and oral cavity cancer and oral squamous cell carcinoma. An important gene associated with Oral Cavity Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, lymph node and tongue, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Decreased viability with paclitaxel

Related Diseases for Oral Cavity Cancer

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 lip and oral cavity cancer 12.5
2 oral squamous cell carcinoma 11.2
3 salivary gland carcinoma 11.2
4 breast intraductal proliferative lesion 10.6 EGFR ERBB2
5 geographic tongue 10.5 EGFR TNFRSF10B VEGFA
6 primary peritoneal carcinoma 10.5 EGFR ERBB2 VEGFA
7 breast carcinoma in situ 10.5 EGFR ERBB2 VEGFA
8 pharynx cancer 10.5 EGFR GSTM1 VEGFA
9 esophageal disease 10.5 ALDH2 EGFR ERBB2
10 oral cancer 10.5 CYP1A1 EGFR GSTM1
11 stomach disease 10.5 EGFR ERBB2 VEGFA
12 colonic disease 10.4 EDNRB EGFR VEGFA
13 progesterone-receptor negative breast cancer 10.4 EGFR ERBB2
14 nervous system cancer 10.4 EGFR PTEN VEGFA
15 breast squamous cell carcinoma 10.4 EGFR ERBB2 PIK3CA
16 sister chromatid exchange, frequency of 10.4 ALDH2 GSTM1
17 breast disease 10.4 BAX CYP1A1 ERBB2 SOD2 VEGFA
18 breast scirrhous carcinoma 10.4 EGFR ERBB2
19 adenosquamous lung carcinoma 10.4 EGFR ERBB2 PIK3CA
20 acneiform dermatitis 10.4 CYP1A1 EGFR ERBB2 PIK3CA
21 ovarian cancer 1 10.4 ERBB2 PIK3CA VEGFA
22 malignant ovarian surface epithelial-stromal neoplasm 10.4 ERBB2 PIK3CA VEGFA
23 ovary epithelial cancer 10.4 ERBB2 PIK3CA VEGFA
24 myeloma, multiple 10.4 BST2 CASP8 MCL1 VEGFA
25 ovary adenocarcinoma 10.4 BAX ERBB2 PIK3CA
26 supratentorial cancer 10.4 EGFR PTEN SOX2 VEGFA
27 serous cystadenocarcinoma 10.4 ERBB2 PIK3CA VEGFA
28 cerebrum cancer 10.4 EGFR PTEN SOX2 VEGFA
29 estrogen-receptor positive breast cancer 10.4 EGFR ERBB2 PIK3CA
30 cystadenocarcinoma 10.4 ERBB2 PIK3CA VEGFA
31 central nervous system cancer 10.4 EGFR PTEN SOX2 VEGFA
32 female reproductive system disease 10.4 EGFR ERBB2 PTEN VEGFA
33 reproductive system disease 10.4 EGFR ERBB2 PTEN VEGFA
34 endometrial adenocarcinoma 10.4 EGFR ERBB2 PTEN VEGFA
35 pancreas adenocarcinoma 10.4 EGFR ERBB2 PIK3CA VEGFA
36 mucinous stomach adenocarcinoma 10.4 PTEN VEGFA
37 adult hepatocellular carcinoma 10.4 CASP8 PIK3CA
38 endocrine gland cancer 10.4 EGFR ERBB2 PTEN VEGFA
39 grade iii astrocytoma 10.4 EGFR PTEN VEGFA
40 intestinal disease 10.3 EDNRB EGFR PIK3CA VEGFA
41 acute t cell leukemia 10.3 BAX CASP8 PTEN
42 ovarian serous cystadenocarcinoma 10.3 BAX ERBB2 PIK3CA
43 carcinosarcoma 10.3 ERBB2 PIK3CA PTEN
44 thyroid hurthle cell adenoma 10.3 PIK3CA PTEN
45 lung cancer susceptibility 3 10.3 CASP8 CYP1A1 EGFR ERBB2 PIK3CA VEGFA
46 uterine anomalies 10.3 ERBB2 PIK3CA PTEN VEGFA
47 uterine carcinosarcoma 10.2 EGFR ERBB2 PIK3CA PTEN
48 adenocarcinoma 10.2 EGFR ERBB2 PIK3CA PTEN VEGFA
49 lymphoma, non-hodgkin, familial 10.2 BAX CASP8 MCL1 PIK3CA
50 gastrointestinal system cancer 10.2 EGFR ERBB2 PIK3CA PTEN VEGFA

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:



Diseases related to Oral Cavity Cancer

Symptoms & Phenotypes for Oral Cavity Cancer

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 EGFR ERBB2 GSTM1 PTEN VEGFA
2 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 FADD
3 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Oral Cavity Cancer:

47 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.48 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
2 cardiovascular system MP:0005385 10.46 ALDH2 CASP8 CYP1A1 EDNRB EGFR ERBB2
3 homeostasis/metabolism MP:0005376 10.46 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
4 cellular MP:0005384 10.45 ALDH2 BAX CASP8 EDNRB EGFR ERBB2
5 endocrine/exocrine gland MP:0005379 10.43 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
6 mortality/aging MP:0010768 10.42 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
7 immune system MP:0005387 10.39 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
8 hematopoietic system MP:0005397 10.38 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
9 behavior/neurological MP:0005386 10.36 ALDH2 BAX EDNRB ERBB2 GDF15 PIK3CA
10 embryo MP:0005380 10.33 CASP8 EDNRB EGFR ERBB2 FADD LIN28B
11 muscle MP:0005369 10.32 ALDH2 BAX CASP8 EDNRB EGFR ERBB2
12 integument MP:0010771 10.31 ALDH2 CASP8 EDNRB EGFR ERBB2 MCL1
13 nervous system MP:0003631 10.31 ALDH2 BAX CASP8 EDNRB EGFR ERBB2
14 neoplasm MP:0002006 10.23 ALDH2 BAX CASP8 EDNRB EGFR ERBB2
15 liver/biliary system MP:0005370 10.21 ALDH2 CASP8 CYP1A1 EGFR FADD GDF15
16 digestive/alimentary MP:0005381 10.2 EDNRB EGFR ERBB2 FADD PTEN SOX2
17 limbs/digits/tail MP:0005371 10.07 ALDH2 BAX EDNRB EGFR ERBB2 PTEN
18 normal MP:0002873 10.06 CYP1A1 EGFR ERBB2 LIN28B MCL1 PTEN
19 renal/urinary system MP:0005367 10.02 ALDH2 BAX CASP8 EDNRB EGFR GDF15
20 reproductive system MP:0005389 9.96 ALDH2 BAX EGFR ERBB2 MCL1 PIK3CA
21 pigmentation MP:0001186 9.85 ALDH2 EDNRB EGFR PTEN SOD2 SOX2
22 respiratory system MP:0005388 9.81 BAX CASP8 EDNRB EGFR ERBB2 PTEN
23 skeleton MP:0005390 9.7 ALDH2 BAX EDNRB EGFR ERBB2 FADD
24 vision/eye MP:0005391 9.28 ALDH2 BAX EDNRB EGFR PIK3CA PTEN

Drugs & Therapeutics for Oral Cavity Cancer

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 426)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 4,Phase 2,Phase 1 329-65-7 838
2
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
3
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
4
Dopamine Approved Phase 4,Phase 2,Not Applicable 62-31-7, 51-61-6 681
5
Dobutamine Approved Phase 4,Not Applicable 34368-04-2 36811
6
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
7
Pentetic acid Approved Phase 4 67-43-6
8
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
9
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
10
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
11
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
12
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-70-2 271
13 Mydriatics Phase 4,Phase 2
14 Adrenergic beta-Agonists Phase 4,Phase 2,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
17 Vasoconstrictor Agents Phase 4,Phase 2,Phase 1,Not Applicable
18 Anti-Asthmatic Agents Phase 4,Phase 2
19 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
21 Sympathomimetics Phase 4,Phase 2,Not Applicable
22 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Not Applicable
23 Epinephryl borate Phase 4,Phase 2,Phase 1
24 Bronchodilator Agents Phase 4,Phase 2
25 Adrenergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
26 Respiratory System Agents Phase 4,Phase 2,Not Applicable
27 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Radiopharmaceuticals Phase 4,Phase 1,Phase 2,Not Applicable
29 Anticoagulants Phase 4,Not Applicable
30 Chelating Agents Phase 4,Not Applicable,Early Phase 1
31 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
32 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Calcium, Dietary Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
34 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
35
protease inhibitors Phase 4,Phase 2,Phase 3
36 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Vasodilator Agents Phase 4,Not Applicable
38 Dopamine Agents Phase 4,Phase 2,Not Applicable
39 Dopamine agonists Phase 4
40 Cardiotonic Agents Phase 4,Not Applicable
41 Blood Substitutes Phase 4
42 Plasma Substitutes Phase 4
43 Dextrans Phase 4
44 Technetium Tc 99m Pentetate Phase 4
45 Technetium Tc 99m Sulfur Colloid Phase 4,Not Applicable
46 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
47 Antidepressive Agents Phase 4,Phase 3,Phase 2
48 Antidepressive Agents, Second-Generation Phase 4,Phase 2
49 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
50 Dopamine Uptake Inhibitors Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 601)
# Name Status NCT ID Phase Drugs
1 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
2 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
3 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
6 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
7 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
8 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions Recruiting NCT03684707 Phase 4 Metformin Hcl 500Mg 24Hr Sa Tab
9 Aliskiren Study of Safety and Efficacy in Senior Hypertensives Withdrawn NCT01922141 Phase 4 Aliskiren;Amlodipine;Ramipril;Hydrochlorothiazide
10 Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Unknown status NCT00655421 Phase 3
11 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
12 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
13 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
14 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
15 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Unknown status NCT00964977 Phase 3
16 The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation Unknown status NCT00815893 Phase 2, Phase 3 dexmedetomidine;Normal Saline 0.9%;propofol 1%
17 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
18 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
19 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
20 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
21 Erlotinib Prevention of Oral Cancer (EPOC) Completed NCT00402779 Phase 3 Erlotinib;Placebo
22 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
23 Efficacy of Zinc on Concurrent Chemo-radiotherapy Induced Taste Alterations Completed NCT03824925 Phase 3 Placebo oral Zinc capsule;Zinc Sulfate 220 MG
24 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
25 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
26 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
27 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3 13-cis Retino Acid
28 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
29 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
30 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
31 Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers Completed NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
32 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
33 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
34 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
35 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
36 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
37 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
38 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
39 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
40 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
41 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
42 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
43 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
44 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
45 The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Completed NCT01414790 Phase 3
46 Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
47 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Recruiting NCT03237325 Phase 3 SGX942;Placebo
48 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
49 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
50 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Active, not recruiting NCT01265849 Phase 3 Cyclophosphamide;Indomethacin;Cisplatin

Search NIH Clinical Center for Oral Cavity Cancer

Genetic Tests for Oral Cavity Cancer

Anatomical Context for Oral Cavity Cancer

MalaCards organs/tissues related to Oral Cavity Cancer:

42
Salivary Gland, Lymph Node, Tongue, Brain, Skin, Testes, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

20
The Oral Cavity

Publications for Oral Cavity Cancer

Articles related to Oral Cavity Cancer:

(show top 50) (show all 334)
# Title Authors Year
1
Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Stage I to II Oral Cavity Cancer. ( 30284248 )
2019
2
Comparison of psychosocial factors over time among HPV+ oropharyngeal cancer and tobacco-related oral cavity cancer patients. ( 30322742 )
2019
3
Does anatomic subsite influence oral cavity cancer mortality? A SEER database analysis. ( 30408182 )
2019
4
Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients With Oral Cavity Cancer. ( 30452499 )
2019
5
Oral Cavity Cancer. ( 30454788 )
2019
6
Oral cavity cancer management guidelines for low-resource regions. ( 30666743 )
2019
7
Commentary on "Number of positive lymph nodes better predicts survival for oral cavity cancer" by Hojun Lee et al. ( 30672589 )
2019
8
Number of positive lymph nodes better predicts survival for oral cavity cancer. ( 30672597 )
2019
9
Finding an oral potentially malignant disorder in screening program is related to early diagnosis of oral cavity cancer - Experience from real world evidence. ( 30732947 )
2019
10
Impact of postoperative radiation therapy for deeply invasive oral cavity cancer upstaged to stage III. ( 30773733 )
2019
11
Number of positive nodes - Current relevance in determining prognosis of oral cavity cancer after the recent AJCC staging update. ( 30846166 )
2019
12
Delays in oral cavity cancer. ( 30878273 )
2019
13
Factors influencing body image in posttreatment oral cavity cancer patients. ( 30889623 )
2019
14
Does Clearance of Positive Margins Improve Local Control in Oral Cavity Cancer? A Meta-analysis. ( 30912991 )
2019
15
Human papillomavirus DNA detection, p16INK4a, and oral cavity cancer in a U.S. population. ( 30926069 )
2019
16
Relevant changes in the AJCC 8th edition staging manual for oral cavity cancer and future implications. ( 30943732 )
2019
17
Alterations in XRCC1 gene profile in pathogenesis of oral cavity cancer: A population-based study from Kamrup Urban District of Assam, India. ( 30954277 )
2019
18
Association between coffee intake and the risk of oral cavity cancer: a meta-analysis of observational studies. ( 31021885 )
2019
19
Inclusion of Neck Level IV in Treatment of Patients With Clinically Node-Negative Oral Cavity Cancer. ( 31070695 )
2019
20
Early Postoperative Oral Exercise Improves Swallowing Function Among Patients With Oral Cavity Cancer: A Randomized Controlled Trial. ( 31088304 )
2019
21
Complete atrioventricular block as an initial manifestation of recurred oral cavity cancer: a case report. ( 29986652 )
2018
22
Combination of recurrent oral aphthae and dry eye syndrome may constitute an independent risk factor for oral cavity cancer in elderly women. ( 30233243 )
2018
23
Swallowing ability and its impact on dysphagia-specific health-related QOL in oral cavity cancer patients post-treatment. ( 30322515 )
2018
24
Effects of a swallowing exercise education program on dysphagia-specific health-related quality of life in oral cavity cancer patients post-treatment: a randomized controlled trial. ( 29546525 )
2018
25
The effectiveness of a saline mouth rinse regimen and education programme on radiation-induced oral mucositis and quality of life in oral cavity cancer patients: A randomised controlled trial. ( 29315944 )
2018
26
The influence of insurance status on treatment and outcomes in oral cavity cancer: an analysis on 46,373 patients. ( 29655817 )
2018
27
Locoregionally advanced oral cavity cancer: A propensity-score matched analysis on overall survival with emphasis on the impact of adjuvant radiotherapy. ( 29665118 )
2018
28
The influence of marital status on survival for patients aged 65 years and younger with oral cavity cancer. ( 29685504 )
2018
29
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. ( 29706184 )
2018
30
Detection of cervical lymph node metastasis from oral cavity cancer using a non-radiating, noninvasive digital infrared thermal imaging system. ( 29739969 )
2018
31
Opioid prescribing practices in patients undergoing surgery for oral cavity cancer. ( 29756393 )
2018
32
Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis. ( 29761306 )
2018
33
Expression profiles of selected genes in tumors and matched surgical margins in oral cavity cancer: Do we have to pay attention to the molecular analysis of the surgical margins? ( 29790687 )
2018
34
Can MR textural analysis improve the prediction of extracapsular nodal spread in patients with oral cavity cancer? ( 29872911 )
2018
35
Aberrant DNA methylation of the p16, APC, MGMT, TIMP3 and CDH1 gene promoters in tumours and the surgical margins of patients with oral cavity cancer. ( 29896273 )
2018
36
Author Correction: Detection of cervical lymph node metastasis from oral cavity cancer using a non-radiating, noninvasive digital infrared thermal imaging system. ( 29991743 )
2018
37
Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. ( 30220313 )
2018
38
Toward complete oral cavity cancer resection using a handheld diffuse reflectance spectroscopy probe. ( 30341837 )
2018
39
Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution. ( 30349385 )
2018
40
Evaluation of early oral cavity cancer treatment quality at a single institution. ( 30408196 )
2018
41
Clinical analysis of neck node metastasis in oral cavity cancer. ( 30637242 )
2018
42
Untreated oral cavity cancer: Long-term survival and factors associated with treatment refusal. ( 28865100 )
2018
43
Factors associated with continued smoking after treatment of oral cavity cancer: An age and survival time-matched study. ( 29148210 )
2018
44
Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. ( 29256326 )
2018
45
Association of Time between Surgery and Adjuvant Therapy with Survival in Oral Cavity Cancer. ( 29313448 )
2018
46
Genetic analysis of surgical margins in oral cavity cancer. ( 29341160 )
2018
47
Narrow Band Imaging-guided resection of oral cavity cancer decreases local recurrence and increases survival. ( 29480612 )
2018
48
Detection of surgical margins in oral cavity cancer: the role of dynamic optical contrast imaging. ( 29517537 )
2018
49
High sensitivity and negative predictive value of sentinel lymph node biopsy in a retrospective early stage oral cavity cancer cohort in the Northern Netherlands. ( 29575685 )
2018
50
MR lymphography for sentinel lymph node detection in patients with oral cavity cancer: Preliminary clinical study. ( 29633413 )
2018

Variations for Oral Cavity Cancer

ClinVar genetic disease variations for Oral Cavity Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
2 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh38 Chromosome 3, 179234296: 179234296
3 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
4 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh38 Chromosome 10, 87933147: 87933147
5 PIK3CA NM_006218.3(PIK3CA): c.3145G> C (p.Gly1049Arg) single nucleotide variant Likely pathogenic rs121913277 GRCh37 Chromosome 3, 178952090: 178952090
6 PIK3CA NM_006218.3(PIK3CA): c.3145G> C (p.Gly1049Arg) single nucleotide variant Likely pathogenic rs121913277 GRCh38 Chromosome 3, 179234302: 179234302

Expression for Oral Cavity Cancer

Search GEO for disease gene expression data for Oral Cavity Cancer.

Pathways for Oral Cavity Cancer

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 BST2 CASP8 EGFR ERBB2 FADD MCL1
2
Show member pathways
13.87 BAX CASP8 EGFR ERBB2 FADD GDF15
3
Show member pathways
13.4 BAX EGFR ERBB2 FADD GDF15 PTEN
4
Show member pathways
13.37 BST2 EGFR ERBB2 MCL1 PIK3CA SOX2
5
Show member pathways
13.31 BAX CASP8 EGFR ERBB2 GDF15 PTEN
6
Show member pathways
12.93 CASP8 EDNRB EGFR FADD PIK3CA TNFRSF10B
7
Show member pathways
12.89 EGFR ERBB2 PIK3CA PTEN VEGFA
8
Show member pathways
12.88 BAX CASP8 EGFR FADD PIK3CA PTEN
9
Show member pathways
12.84 BAX EGFR ERBB2 PIK3CA PTEN VEGFA
10
Show member pathways
12.82 BAX BST2 CASP8 EGFR FADD PIK3CA
11
Show member pathways
12.79 BAX CASP8 FADD MCL1 PIK3CA TNFRSF10B
12
Show member pathways
12.73 BAX EGFR ERBB2 GSTM1 PIK3CA PTEN
13
Show member pathways
12.69 BAX CASP8 EGFR ERBB2 FADD MCL1
14
Show member pathways
12.66 BAX EGFR ERBB2 PIK3CA PTEN VEGFA
15
Show member pathways
12.58 EGFR ERBB2 PIK3CA VEGFA
16
Show member pathways
12.58 CASP8 FADD PIK3CA TLR2 TNFRSF10B VEGFA
17
Show member pathways
12.57 CASP8 EGFR FADD PIK3CA PTEN TNFRSF10B
18
Show member pathways
12.49 EGFR ERBB2 PIK3CA PTEN
19
Show member pathways
12.48 BAX ERBB2 PIK3CA PTEN
20 12.46 EGFR ERBB2 MCL1 PIK3CA PTEN VEGFA
21
Show member pathways
12.42 BAX CASP8 EGFR ERBB2 PIK3CA
22
Show member pathways
12.38 BAX CASP8 PTEN TNFRSF10B
23
Show member pathways
12.3 CASP8 FADD PIK3CA TNFRSF10B
24
Show member pathways
12.26 BAX CASP8 PTEN TNFRSF10B
25 12.25 EGFR ERBB2 PIK3CA TLR2 VEGFA
26 12.24 BAX CASP8 FADD TLR2
27
Show member pathways
12.23 BAX CASP8 FADD TNFRSF10B
28 12.19 BAX EGFR TLR2 VEGFA
29
Show member pathways
12.19 BAX EGFR ERBB2 PIK3CA PTEN
30 12.15 BAX CASP8 FADD GDF15 MCL1 TNFRSF10B
31
Show member pathways
12.13 EGFR ERBB2 PIK3CA PTEN
32
Show member pathways
12.1 EGFR ERBB2 PIK3CA PTEN
33
Show member pathways
12.09 BAX EGFR GDF15 PIK3CA TNFRSF10B
34 12.09 BAX EGFR ERBB2 PIK3CA PTEN
35
Show member pathways
12.07 EGFR PIK3CA PTEN SOD2
36 12.05 BAX CASP8 EDNRB EGFR ERBB2 FADD
37 11.99 BAX CASP8 EGFR FADD PTEN VEGFA
38
Show member pathways
11.97 CASP8 EGFR ERBB2 PIK3CA TLR2
39 11.92 BAX ERBB2 PIK3CA PTEN SOD2
40 11.9 BAX PIK3CA VEGFA
41 11.88 EGFR ERBB2 PIK3CA VEGFA
42 11.86 BAX PIK3CA PTEN
43
Show member pathways
11.86 EGFR ERBB2 VEGFA
44 11.85 BAX EGFR GDF15 MCL1 PTEN TNFRSF10B
45
Show member pathways
11.81 BAX CASP8 PIK3CA
46
Show member pathways
11.78 BAX CASP8 FADD MCL1
47 11.75 EGFR ERBB2 VEGFA
48 11.7 ERBB2 PIK3CA PTEN
49 11.64 EGFR ERBB2 PIK3CA PTEN
50 11.57 BAX EGFR MCL1

GO Terms for Oral Cavity Cancer

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.86 BAX BST2 CASP8 CYP1A1 EGFR ERBB2
2 cell body GO:0044297 9.58 CASP8 FADD TLR2
3 death-inducing signaling complex GO:0031264 9.37 CASP8 FADD
4 Bcl-2 family protein complex GO:0097136 9.32 BAX MCL1
5 CD95 death-inducing signaling complex GO:0031265 9.26 CASP8 FADD
6 ripoptosome GO:0097342 9.16 CASP8 FADD
7 membrane raft GO:0045121 9.1 BST2 CASP8 EDNRB EGFR FADD TLR2

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.98 MCL1 PIK3CA SOX2 VEGFA
2 apoptotic process GO:0006915 9.98 BAX CASP8 FADD MCL1 PTEN TLR2
3 negative regulation of apoptotic process GO:0043066 9.95 EDNRB EGFR MCL1 PTEN VEGFA
4 positive regulation of protein phosphorylation GO:0001934 9.91 EDNRB EGFR ERBB2 VEGFA
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.89 BST2 CASP8 FADD TNFRSF10B
6 positive regulation of protein kinase B signaling GO:0051897 9.88 EGFR ERBB2 GDF15 PIK3CA
7 response to lipopolysaccharide GO:0032496 9.88 CASP8 CYP1A1 EDNRB TLR2
8 response to toxic substance GO:0009636 9.85 BAX CYP1A1 TLR2
9 cell proliferation GO:0008283 9.85 BAX BST2 CYP1A1 EGFR ERBB2 PTEN
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 EGFR PIK3CA VEGFA
11 liver development GO:0001889 9.83 CYP1A1 EGFR PIK3CA
12 response to organic cyclic compound GO:0014070 9.83 CYP1A1 EDNRB EGFR PTEN
13 response to wounding GO:0009611 9.82 BAX CYP1A1 SOX2
14 apoptotic signaling pathway GO:0097190 9.81 BAX CASP8 FADD
15 positive regulation of epithelial cell proliferation GO:0050679 9.8 EGFR ERBB2 VEGFA
16 positive regulation of MAP kinase activity GO:0043406 9.8 EGFR ERBB2 VEGFA
17 aging GO:0007568 9.77 CYP1A1 EDNRB PTEN
18 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.76 BAX CASP8 FADD TNFRSF10B
19 extrinsic apoptotic signaling pathway GO:0097191 9.74 BAX CASP8 FADD
20 cell surface receptor signaling pathway GO:0007166 9.73 CASP8 EDNRB EGFR ERBB2 FADD TNFRSF10B
21 positive regulation of MAPK cascade GO:0043410 9.71 ERBB2 GDF15 SOX2
22 cellular response to mechanical stimulus GO:0071260 9.71 CASP8 EGFR FADD TNFRSF10B
23 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.69 CASP8 FADD TNFRSF10B
24 negative regulation of phagocytosis GO:0050765 9.68 PTEN TLR2
25 activation of cysteine-type endopeptidase activity GO:0097202 9.67 CASP8 FADD
26 positive regulation of macrophage differentiation GO:0045651 9.67 CASP8 FADD
27 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.67 BAX SOX2
28 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.67 BAX FADD MCL1
29 response to arsenic-containing substance GO:0046685 9.66 CYP1A1 PTEN
30 toll-like receptor 3 signaling pathway GO:0034138 9.65 CASP8 FADD
31 ERBB2 signaling pathway GO:0038128 9.65 EGFR ERBB2 PIK3CA
32 death-inducing signaling complex assembly GO:0071550 9.64 CASP8 FADD
33 regulation of apoptotic process GO:0042981 9.63 BAX CASP8 FADD GDF15 MCL1 TNFRSF10B
34 regulation of necroptotic process GO:0060544 9.62 CASP8 FADD
35 negative regulation of ERBB signaling pathway GO:1901185 9.61 EGFR ERBB2
36 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.56 BAX CASP8
37 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.5 CASP8 FADD TNFRSF10B
38 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.26 BAX CASP8 FADD TNFRSF10B
39 TRAIL-activated apoptotic signaling pathway GO:0036462 8.8 CASP8 FADD TNFRSF10B
40 nervous system development GO:0007399 10.05 BAX EDNRB ERBB2 PTEN VEGFA

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.88 BAX BST2 GDF15 GSTM1 MCL1 VEGFA
2 death receptor binding GO:0005123 9.46 CASP8 FADD
3 platelet-derived growth factor receptor binding GO:0005161 9.43 PTEN VEGFA
4 protein heterodimerization activity GO:0046982 9.43 BAX EGFR ERBB2 MCL1 TLR2 VEGFA
5 identical protein binding GO:0042802 9.32 BAX BST2 CASP8 EGFR ERBB2 FADD
6 BH3 domain binding GO:0051434 9.26 BAX MCL1
7 death effector domain binding GO:0035877 9.16 CASP8 FADD
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.07 PIK3CA
9 protein binding GO:0005515 10.25 BAX BST2 CASP8 CYP1A1 EDNRB EGFR

Sources for Oral Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....